One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the impact of ziprasidone on the distribution of
metabolic syndrome risk factors in a population of patients presenting with glucose
intolerance, dyslipidemia and/or elevated waist circumference associated with their current
antipsychotic medication.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.